Assetmark Inc. lifted its holdings in Novo Nordisk A/S (NYSE:NVO) by 10.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 226,179 shares of the company’s stock after buying an additional 21,124 shares during the period. Assetmark Inc.’s holdings in Novo Nordisk A/S were worth $10,662,000 as of its most recent SEC filing.
Several other institutional investors have also modified their holdings of NVO. Chicago Partners Investment Group LLC boosted its position in Novo Nordisk A/S by 762.5% during the second quarter. Chicago Partners Investment Group LLC now owns 3,131 shares of the company’s stock valued at $144,000 after purchasing an additional 2,768 shares during the last quarter. Legacy Financial Advisors Inc. boosted its position in Novo Nordisk A/S by 527.8% during the third quarter. Legacy Financial Advisors Inc. now owns 3,886 shares of the company’s stock valued at $183,000 after purchasing an additional 3,267 shares during the last quarter. Schroder Investment Management Group acquired a new stake in Novo Nordisk A/S during the second quarter valued at $182,000. Stevens Capital Management LP acquired a new stake in Novo Nordisk A/S during the second quarter valued at $202,000. Finally, FineMark National Bank & Trust acquired a new stake in Novo Nordisk A/S during the third quarter valued at $212,000. 6.84% of the stock is owned by institutional investors and hedge funds.
A number of analysts recently issued reports on NVO shares. Deutsche Bank reissued a “buy” rating on shares of Novo Nordisk A/S in a research report on Thursday, October 4th. Zacks Investment Research raised Novo Nordisk A/S from a “sell” rating to a “hold” rating in a research report on Tuesday, November 20th. HSBC reaffirmed a “sell” rating on shares of Novo Nordisk A/S in a research report on Tuesday, November 6th. UBS Group reaffirmed a “buy” rating on shares of Novo Nordisk A/S in a research report on Monday, November 26th. Finally, Guggenheim began coverage on Novo Nordisk A/S in a research report on Monday, October 8th. They issued a “buy” rating for the company. One analyst has rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and a consensus price target of $64.00.
Shares of NYSE:NVO opened at $45.38 on Friday. Novo Nordisk A/S has a fifty-two week low of $41.23 and a fifty-two week high of $58.37. The stock has a market capitalization of $111.62 billion, a price-to-earnings ratio of 19.39, a P/E/G ratio of 2.41 and a beta of 0.75.
Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Thursday, November 1st. The company reported $0.58 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.58. Novo Nordisk A/S had a return on equity of 81.50% and a net margin of 34.94%. The company had revenue of $4.31 billion during the quarter, compared to analysts’ expectations of $4.11 billion. Sell-side analysts expect that Novo Nordisk A/S will post 2.45 EPS for the current fiscal year.
Novo Nordisk A/S Profile
Novo Nordisk A/S, a healthcare company, engages in the discovery, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides insulins, GLP-1 and related delivery systems, and oral anti-diabetic drugs and obesity.
Featured Story: Intrinsic Value and Stock Selection
Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO).
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.